Intermune ($ITMN) says it will begin enrollment of another late-stage trial of idiopathic pulmonary fibrosis drug pirfenidone in the first half of 2011. Eight months ago, the FDA rejected the company's application for approval, noting that another trial would be necessary if the company ever hopes to sell the drug in the U.S. Intermune has seen success in Europe, however, where a panel of experts issued a positive opinion of the drug in late 2010. Report